Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) Research & Development (2016 - 2026)

Myriad Genetics has reported Research & Development over the past 17 years, most recently at $25.5 million for Q4 2025.

  • Quarterly Research & Development fell 20.81% to $25.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.8 million through Dec 2025, down 5.24% year-over-year, with the annual reading at $106.8 million for FY2025, 5.82% down from the prior year.
  • Research & Development was $25.5 million for Q4 2025 at Myriad Genetics, down from $28.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $32.2 million in Q4 2024 and troughed at $18.8 million in Q3 2021.
  • The 5-year median for Research & Development is $23.2 million (2021), against an average of $23.8 million.
  • Year-over-year, Research & Development plummeted 42.74% in 2021 and then soared 53.33% in 2024.
  • A 5-year view of Research & Development shows it stood at $20.5 million in 2021, then rose by 14.15% to $23.4 million in 2022, then decreased by 10.26% to $21.0 million in 2023, then skyrocketed by 53.33% to $32.2 million in 2024, then fell by 20.81% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Research & Development are $25.5 million (Q4 2025), $28.2 million (Q3 2025), and $25.6 million (Q2 2025).